Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age. The criteria required for the diagnosis identify various phenotypes, with different reproductive, metabolic, and cardiovascular (CV) risk characteristics. Emerging evidence links adipocyte-secreted hormones as candidates in the pathogenesis of endothelial dysfunction in PCOS, independently of additional risk factors. The aim of this review was to collect, analyze, and qualitatively resynthesize evidence on biomarkers of endothelial dysfunction (visfatin, vascular endothelial growth factor [VEGF], matrix metalloproteinase 9 [MMP-9]) in women with PCOS. Women with PCOS exhibit (a) increased plasma visfatin concentrations compared with controls with a similar body mass index; (b) increased VEGF production along with chronic, mild inflammation; and (c) increased MMP-9 concentrations, which might be related to either excessive CV risk or abnormalities of ovarian extracellular matrix remodeling, multiple cyst formation, follicular atresia, and chronic anovulation. As PCOS has been associated with CV risk, early identification of endothelial dysfunction is clinically relevant.

• Publication year

  2019

• Venue

  Angiology

• Publication date

  2019-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0003319719840091PMID 30969784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

  2019cited by this paper
• Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences.

  2017cited by this paper
• Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS

  2017cited by this paper
• Serum visfatin levels in women with polycystic ovary syndrome

  2012cited by this paper
• Plasma visfatin level in women with polycystic ovary syndrome

  2011influential reference
• Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome

  2011cited by this paper
• Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review.

  2010cited by this paper
• The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.

  2010cited by this paper
• Noninvasive methods for assessing early markers of atherosclerosis: the role of body composition and nutrition

  2009cited by this paper
• Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1

  2008cited by this paper
• Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.

  2007cited by this paper
• Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women.

  2007cited by this paper
• Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

  2007cited by this paper
• Increased plasma visfatin concentrations in women with polycystic ovary syndrome.

  2007cited by this paper
• Polycystic ovary syndrome

  2007cited by this paper
• The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells

  2007cited by this paper
• The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis

  2006cited by this paper
• Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome.

  2006cited by this paper
• PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factors

  2006cited by this paper
• Endothelial signalling events during leukocyte transmigration

  2006cited by this paper
• Visfatin is an adipokine, but it is not regulated by thiazolidinediones.

  2006cited by this paper
• Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.

  2006cited by this paper
• Visfatin: the missing link between intra-abdominal obesity and diabetes?

  2005cited by this paper
• Adipose tissue, adipokines, and inflammation.

  2005cited by this paper
• Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin

  2005cited by this paper
• Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.

  2005cited by this paper
• Circulating endothelial cells

  2005cited by this paper
• Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

  2005cited by this paper
• Endothelial cells and VEGF in vascular development

  2005cited by this paper
• MMPS and TIMPS in ovarian physiology and pathophysiology.

  2004influential reference
• The Framingham Heart Study

  2004cited by this paper
• Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein.

  2003cited by this paper
• Growth phase‐dependent changes in the subcellular localization of pre‐B‐cell colony‐enhancing factor 1

  2003cited by this paper
• Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease

  2003cited by this paper
• Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry

  2003cited by this paper
• Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization.

  2003cited by this paper
• Endothelial Dysfunction: A Marker of Atherosclerotic Risk

  2003cited by this paper
• Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome.

  2003cited by this paper
• Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms.

  2002cited by this paper
• Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes.

  2002cited by this paper
• Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease.

  2002cited by this paper
• Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes.

  2001cited by this paper
• Tissue inhibitors of metalloproteinases: evolution, structure and function.

  2000cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

  2000cited by this paper
• A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

  1999cited by this paper
• Nitric oxide modulation of focal adhesions in endothelial cells.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain*

  1999cited by this paper
• Nitric oxide modulation of focal adhesions in endothelial cells.

  1999cited by this paper
• Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.

  1999cited by this paper
• Caspase-mediated Cleavage of Focal Adhesion Kinase pp125FAK and Disassembly of Focal Adhesions in Human Endothelial Cell Apoptosis

  1998cited by this paper
• Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.

  1998cited by this paper
• Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

  1998cited by this paper
• Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins*

  1998cited by this paper
• Characterization of signal transduction pathways in human bone marrow endothelial cells.

  1997cited by this paper
• Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins.

  1997cited by this paper
• Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells*

  1997cited by this paper
• Characterization of Signal Transduction Pathways in Human Bone Marrow Endothelial Cells

  1997cited by this paper
• Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model.

  1997cited by this paper
• Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase

  1997cited by this paper
• Coronary heart disease risk factors in women with polycystic ovary syndrome.

  1995cited by this paper
• Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

  1994cited by this paper
• Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

  1994cited by this paper
• The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent

  1994cited by this paper
• Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration

  1990cited by this paper
• Human vascular permeability factor. Isolation from U937 cells.

  1989cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745–2749 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected

  year unknowncited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study*

  year unknowncited by this paper
• This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinase: Regulation and Dysregulation in the failing Heart Matrix M

  year unknowncited by this paper

• A cross-sectional exploratory study of rat sarcoma (Ras) activation in non-obese women with and without polycystic ovary syndrome

  2026cites this paper
• A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

  2025cites this paper
• Extracellular matrix dysregulation in PCOS: pathogenesis, therapeutic strategies, and innovative technologies

  2025cites this paper
• Identification of crucial pathways and genes linked to endoplasmic reticulum stress in PCOS through combined bioinformatic analysis

  2025cites this paper
• Atherogenic ApoB-dyslipidemia, atherosclerotic cardiovascular disease, cardiac dysfunction and remodeling in high-risk young women with and without polycystic ovary syndrome: A pilot study

  2025cites this paper
• Endothelial Function and Matrix Metalloproteinase 9 (MMP9) in Women with Polycystic Ovary Syndrome (PCOS)

  2025cites this paper
• Association of uric acid and fructose levels in polycystic ovary syndrome.

  2024cites this paper
• Association between interleukin-39 (IL-39) with hormonal and metabolic changes in women with polycystic ovarian syndrome

  2024influential citation
• Visfatin and VEGF levels are not increased in adolescent girls with polycystic ovary syndrome

  2024cites this paper
• Ameliorative potential of rosmarinic acid in a rat model of polycystic ovary syndrome: Targeting MCP‐1 and VEGF: A histological, immunohistochemical, and biochemical study

  2024cites this paper
• Association study to evaluate Foxo1 and Foxo3 gene polymorphisms in polycystic ovary syndrome: a preliminary case–control study and in silico analysis

  2023cites this paper
• The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking

  2023cites this paper
• Modulation of the Inflammatory Response in Polycystic Ovary Syndrome (PCOS)—Searching for Epigenetic Factors

  2022cites this paper
• Cardiovascular Health Does Not Change Following High-Intensity Interval Training in Women with Polycystic Ovary Syndrome

  2022cites this paper
• Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome

  2022cites this paper
• Correlation of Serum Visfatin Level in Non-obese Women with Polycystic Ovary Syndrome and Matched Control

  2022cites this paper
• Gender dimension in cardio-pulmonary continuum

  2022cites this paper
• Endothelial dysfunction: developmental mechanisms and therapeutic strategies

  2022cites this paper
• The “Hitchhiker’s Guide to the Galaxy” of Endothelial Dysfunction Markers in Human Fertility

  2021cites this paper
• Inflammatory Markers Related to Innate and Adaptive Immunity in Atherosclerosis: Implications for Disease Prediction and Prospective Therapeutics

  2021cites this paper
• Influence of Vitamin D on the Vasoactive Effect of Estradiol in a Rat Model of Polycystic Ovary Syndrome

  2021influential citation
• Cardiovascular risk assessment and association with novel biomarkers in patients with Type 2 diabetes mellitus.

  2021cites this paper
• The Association Between Genetically Predicted Systemic Inflammatory Regulators and Polycystic Ovary Syndrome: A Mendelian Randomization Study

  2021cites this paper
• The ovarian stroma as a new frontier.

  2020cites this paper
• Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastocytosis.

  2020cites this paper
• Influence of n-3 fatty acid supplementation on inflammatory and oxidative stress markers in patients with polycystic ovary syndrome: a systematic review and meta-analysis

  2020cites this paper
• Association of vascular endothelial growth factor polymorphisms with polycystic ovarian syndrome risk: a meta-analysis

  2020cites this paper